microRNA Biomarkers to Generate Sensitivity to Abiraterone-Resistant Prostate Cancer
Technical Report,15 Aug 2016,14 Aug 2017
University of Cincinnati Cincinnati United States
Pagination or Media Count:
We plan to develop a combination therapeutic approach, employing Abiraterone Abi plus RNA therapy. For this, we will use an aptamer specific for PSMA aptPSMA to specifically target CRPC cells. The affinity and high specificity of aptPSMA for binding human CRPC cells expressing PSMA has already been reported, as has its utility as a drug delivery system for siRNAs. However, it has not been used to deliver pre-miRNA to cells. Identification of Abi-R markers is important for designing therapeutic interventions sensitizing PCas to combination therapies and for prognostic applications to monitor and predict for disease relapse Abi-R. Additionally, we propose to use patient derived PCa xenograft animal model PCa-PDX mice to identify differentially expressed microRNA miRNA on castration and Abi dependent tumor regression followed by regrowthrelapse. Our central hypothesis is that changes in miRNA expression underlie Abi-R mechanisms and that PCa-PDX mice will be excellent surrogates to identify markers for Abi-R. We further postulate that RNA therapyrestoring or targeting miRNA should increase sensitivity of Abi-R tumors, allowing us to prolong treatments, and hence the life of a patient. Our Aims 1 To develop RNA aptamer therapy. We will test 8 of the recently identified Abi regulated miRNAs for therapeutic utility in vitro. We will design an aptPSMA-pre-miRNA therapeutic delivery vehicle for CRPC-tissue specific delivery. The best miRNA will be used for in vivo studies 2 To generate Abi-R PDX mice and identify the differentially expressed miRNA.
- Medicine and Medical Research